Biogen BIIB Fumarate — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's fumarate — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's fumarate — total revenue?
- Biogen (BIIB) reported fumarate — total revenue of $288.5M in Q1 2026.
- How has Biogen's fumarate — total revenue changed year-over-year?
- Biogen's fumarate — total revenue decreased by 16.4% year-over-year, from $344.9M to $288.5M.
- What is the long-term trend for Biogen's fumarate — total revenue?
- Over 4 years (2021 to 2025), Biogen's fumarate — total revenue has grown at a -11.8% compound annual growth rate (CAGR), from $2.36B to $1.43B.
- What does fumarate — total revenue mean?
- This metric represents the total gross revenue generated from the sale of fumarate-based pharmaceutical products within a specific reporting period. It reflects the market demand and commercial performance of the company's core multiple sclerosis portfolio. Tracking this revenue stream is essential for evaluating the product lifecycle and the impact of generic competition on the company's top-line growth.